1,956 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Leonteq Securities AG

Leonteq Securities AG acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 1,956 shares of the medical research company’s stock, valued at approximately $1,133,000.

Several other large investors have also recently bought and sold shares of the stock. Princeton Capital Management LLC increased its stake in Thermo Fisher Scientific by 2.4% during the 4th quarter. Princeton Capital Management LLC now owns 922 shares of the medical research company’s stock valued at $534,000 after buying an additional 22 shares during the period. BlueStem Wealth Partners LLC acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at about $228,000. Kennedy Investment Group acquired a new position in Thermo Fisher Scientific during the 4th quarter valued at about $234,000. Adell Harriman & Carpenter Inc. increased its stake in Thermo Fisher Scientific by 6.4% during the 4th quarter. Adell Harriman & Carpenter Inc. now owns 9,182 shares of the medical research company’s stock valued at $5,321,000 after buying an additional 554 shares during the period. Finally, Atle Fund Management AB grew its stake in shares of Thermo Fisher Scientific by 10.2% in the 4th quarter. Atle Fund Management AB now owns 29,915 shares of the medical research company’s stock worth $17,334,000 after purchasing an additional 2,768 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on TMO. TD Cowen cut their target price on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a research note on Friday, January 30th. Barclays dropped their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. Morgan Stanley reissued an “overweight” rating and set a $620.00 price objective on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. DZ Bank started coverage on Thermo Fisher Scientific in a research note on Friday, March 27th. They set a “buy” rating and a $610.00 price objective for the company. Finally, Robert W. Baird reduced their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $616.10.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $449.43 on Friday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The company has a 50-day moving average of $481.20 and a two-hundred day moving average of $538.80. The stock has a market cap of $167.02 billion, a price-to-earnings ratio of 24.71, a PEG ratio of 2.00 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. During the same period last year, the company posted $5.15 earnings per share. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.34%.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.